Clinical Trials

BreastGastrointestinalOther hematologic neoplasm

260 enrolled

Carcinoma, Stomach Neoplasms, Leukemia, Myeloid, Acute, Triple Negative Breast Neoplasms

NCT04387084 2025-09-05

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Dermatologic

Skin Neoplasms

NCT04047862 2025-08-22

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

446 enrolled 49 charts

Phase 1 Not yet recruiting

Locally Advanced and Metastatic Solid Tumors

NCT07077369 2025-07-22

WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy

Carcinoma, Hepatocellular

NCT06969612 2025-06-06

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06848465 2025-05-11

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

9 enrolled

DermatologicLymphoidThoracic

Colorectal Neoplasms

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1 Terminated

60 enrolled

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT05494762 2025-05-01

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

Phase 1 Terminated

55 enrolled

Phase 1 Active not recruiting

Solid Tumor

NCT05167071 2025-04-27

HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study

53 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT05984602 2025-04-15

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT06916494 2025-04-10

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Genitourinary

Muscle Invasive Bladder Cancer

NCT06541639 2025-03-18

EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors

78 enrolled

Phase 1 Not yet recruiting

Advanced or Recurrent Solid Tumors

NCT06868732 2025-03-11

Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

288 enrolled

Thoracic

Advanced Non-small Cell Lung Cancer

NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

56 enrolled

Pancreatic Ductal Adenocarcinoma

NCT06741982 2024-12-19

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03666143 2024-11-04

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors

216 enrolled 20 charts

Advanced Solid Tumors

NCT05508100 2024-05-24

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

38 enrolled

Advanced Solid Tumor

NCT05533892 2023-12-19

CCGLC-007

30 enrolled

Carcinoma, Hepatocellular

NCT05644626 2023-11-29

Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants

Phase 1 Withdrawn

Solid Tumors

NCT05984342 2023-08-09

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

50 enrolled

Esophageal Squamous Cell Carcinoma

NCT05798533 2023-07-10

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

6 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

Thoracic

High-Risk Resectable NSCLC

NCT05675462 2023-03-06

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

25 enrolled

Carcinoma, Hepatocellular

NCT03287427 2023-02-15

MYPHISMO

27 enrolled

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Colorectal Neoplasms

NCT05659628 2022-12-21

CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05441046 2022-07-06

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

120 enrolled

Malignant Solid Tumors

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

LymphoidOther hematologic neoplasm

75 enrolled 17 charts

Leukemia, Lymphoma, Recurrence

NCT02660034 2021-12-06

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

229 enrolled 46 charts

Solid Tumors

NCT02407990 2021-11-17

Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors